316 related articles for article (PubMed ID: 26099676)
1. (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes.
Wray R; Solnes L; Mena E; Meoded A; Subramaniam RM
PET Clin; 2015 Jul; 10(3):423-30. PubMed ID: 26099676
[TBL] [Abstract][Full Text] [Related]
2. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
3. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
Kwee RM; Marcus C; Sheikhbahaei S; Subramaniam RM
PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
[TBL] [Abstract][Full Text] [Related]
4. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI.
Santra A; Kumar R; Sharma P; Bal C; Kumar A; Julka PK; Malhotra A
Eur J Radiol; 2012 Mar; 81(3):508-13. PubMed ID: 21353420
[TBL] [Abstract][Full Text] [Related]
5. PET/computed tomography and lymphoma.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2013 Sep; 51(5):833-44. PubMed ID: 24010908
[TBL] [Abstract][Full Text] [Related]
6. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
7. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
[TBL] [Abstract][Full Text] [Related]
8. PET/Computed Tomography and Patient Outcomes in Melanoma.
Rohren EM
PET Clin; 2015 Apr; 10(2):243-54. PubMed ID: 25829089
[TBL] [Abstract][Full Text] [Related]
9. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
10. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
[TBL] [Abstract][Full Text] [Related]
11. Fludeoxyglucose F 18 PET-Computed Tomography: Management Changes Effecting Patient Outcomes in Gynecologic Malignancies.
Brunetti JC
PET Clin; 2015 Jul; 10(3):395-409. PubMed ID: 26099674
[TBL] [Abstract][Full Text] [Related]
12. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
Tirumani SH; LaCasce AS; Jacene HA
PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
[TBL] [Abstract][Full Text] [Related]
13. Differentiation between malignant transformation and tumour recurrence by (68)Ga-bombesin and (18)F-FDG-PET, in patients with low grade gliomas.
Seiz M; Dimitrakopoulou-Strauss A; Schubert GA; Weinmann C; Strauss LG; Eisenhut M; Tuettenberg J
Hell J Nucl Med; 2008; 11(3):149-52. PubMed ID: 19081856
[TBL] [Abstract][Full Text] [Related]
14. Utility of brain FDG-PET in primary CNS lymphoma.
Mohile NA; Deangelis LM; Abrey LE
Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
[TBL] [Abstract][Full Text] [Related]
15. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
16. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-fluorodeoxyglucose PET/computed tomography for primary brain tumors.
Segtnan EA; Hess S; Grupe P; Høilund-Carlsen PF
PET Clin; 2015 Jan; 10(1):59-73. PubMed ID: 25455880
[TBL] [Abstract][Full Text] [Related]
18. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
19. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
Parikh U; Marcus C; Sarangi R; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):327-43. PubMed ID: 26099670
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
